Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A

[1]  Xiao-hui Zhang,et al.  Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia , 2018, Annals of Hematology.

[2]  J. Gill,et al.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. , 2017, Blood.

[3]  Z. Sauna,et al.  Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model , 2017, Journal of thrombosis and haemostasis : JTH.

[4]  Kei Xian Tan,et al.  Towards targeted cancer therapy: Aptamer or oncolytic virus? , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  S. Mamidi,et al.  The complement system in cancer: Ambivalence between tumour destruction and promotion. , 2017, Immunobiology.

[6]  C. Bokemeyer,et al.  Expression and release of platelet protein disulphide isomerase in patients with haemophilia A , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  K. Nogami.  The utility of thromboelastography in inherited and acquired bleeding disorders , 2016, British journal of haematology.

[8]  G. Young,et al.  Is some better than none: are TEG and TGA profiles different in severe FVIII‐deficient patients with inhibitors? , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  Yongqiang Zhao,et al.  Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  S M Moghimi,et al.  Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[11]  V. Jiménez‐Yuste,et al.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. , 2014, Blood transfusion = Trasfusione del sangue.

[12]  G. Froldi,et al.  EC50 estimation of antioxidant activity in DPPH· assay using several statistical programs. , 2013, Food chemistry.

[13]  M. Morfini,et al.  Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) , 2013, Thrombosis and Haemostasis.

[14]  Jin-Ru Wang,et al.  Enzyme-free fluorescence aptasensor for amplification detection of human thrombin via target-catalyzed hairpin assembly. , 2012, Biosensors & bioelectronics.

[15]  G. Rivard,et al.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  M. Othman,et al.  Standardization of thromboelastography: a report from the TEG‐ROTEM working group , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  R. Engelbert,et al.  Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score , 2011, Arthritis care & research.

[18]  M. Clerici,et al.  Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile , 2010, Journal of thrombosis and haemostasis : JTH.

[19]  K. Mann,et al.  Discordant fibrin formation in hemophilia , 2009, Journal of thrombosis and haemostasis : JTH.

[20]  Kenichi A. Tanaka,et al.  The Effects of Fibrinogen Levels on Thromboelastometric Variables in the Presence of Thrombocytopenia , 2009, Anesthesia and analgesia.

[21]  N. Taylor,et al.  Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions , 2008, Proceedings of the National Academy of Sciences.

[22]  I. Warrier,et al.  Thromboelastography in children with coagulation factor deficiencies , 2008, British journal of haematology.

[23]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[24]  G. Young,et al.  Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  W. Kreuz,et al.  Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A , 2006, Platelets.

[26]  M. Laffan,et al.  Thrombin generation and phenotypic correlation in haemophilia A , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  H. Hofmann,et al.  Intraarticular application of superparamagnetic nanoparticles and their uptake by synovial membrane—an experimental study in sheep , 2005 .

[28]  F. Rosendaal,et al.  Thirty years of hemophilia treatment in the Netherlands, 1972-2001. , 2004, Blood.

[29]  J. Ahnström,et al.  A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  B. Sørensen,et al.  Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  D. Mikhailidis,et al.  Influence of platelet count and activity on thromboelastography parameters , 2003, Platelets.

[32]  Sultan,et al.  Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[34]  G. Baatrup,et al.  Activity and activation of the complement system in patients being operated on for cancer of the colon. , 1994, The European journal of surgery = Acta chirurgica.

[35]  J. Semple,et al.  Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. , 1991, Blood.

[36]  S. Barni,et al.  Activation of the Complement System during Immunotherapy of Cancer with Interleukin-2: A Possible Explanation of the Capillary Leak Syndrome , 1990, The International journal of biological markers.

[37]  M. Aguado,et al.  Immunoglobulins and the complement system in colorectal cancer , 1989 .

[38]  A. Codina Cazador,et al.  [Immunoglobulins and the complement system in colorectal cancer]. , 1989, Revista espanola de las enfermedades del aparato digestivo.

[39]  J. Kirkwood.  Influence of body size in animals on health and disease , 1983, The Veterinary Record.

[40]  江口 和夫,et al.  肝・胆道疾患の Thrombelastography , 1977 .

[41]  S. Rainsford,et al.  A Three‐Year Study of Adolescent Boys Suffering from Haemophilia and Allied Disorders , 1973, British journal of haematology.